The Rheumatology Research Foundation has infused more than $130 million into rheumatology research, education and training since it was established in 1985. The Foundation’s efforts have been greatly enhanced by the support of Corporate Roundtable (CRT) members. The CRT is a dynamic partnership between the Foundation and members of the pharmaceutical industry committed to furthering the field of rheumatology.
Explore this issueDecember 2015
Also by this Author
The CRT was established in 1998 with the goal of fulfilling the Foundation’s mission to advance research and training to improve the health of people with rheumatic diseases. For Leadership level donors of the CRT, membership provides a unique avenue by which to make a difference in the rheumatology field.
“Research funded by the Foundation drives some of the most innovative work being done in the rheumatology field,” says James Chung, MD, PhD, executive medical director, U.S. Medical Organization at Amgen. “Amgen is proud to be a part of an organization that supports the researchers who are working to advance rheumatology care for patients worldwide.”
“We value our continued partnership with the Rheumatology Research Foundation, which has … strengthened and advanced excellence in rheumatology, [and] also raised the standard of care for today’s patients,” says Jim Salanty, vice president, U.S. Rheumatology, AbbVie. “The Foundation’s mission of advancing research and training to further innovate and improve the health of people with rheumatologic diseases is at the core of everything we do at AbbVie, with the ultimate goal of transforming how patients with autoimmune diseases are treated.”
“Pfizer is honored to continue to provide support for this important program and commends the Rheumatology Research Foundation for its ongoing commitment to fund rheumatology research,” says Andrew Koenig, DO, FACR, Inflammation & Immunology group lead, North America Medical Affairs, Pfizer Inc. “At Pfizer, we are dedicated to addressing the needs of patients with autoimmune and inflammatory conditions and proud to partner with the Rheumatology Research Foundation to support its work in advancing the field of rheumatology.”
Genentech Inc. is a Pinnacle level donor. Principal level donors include AstraZeneca, Celgene Corp., Eli Lilly and Co., Novartis and UCB. Partner level donors include Bristol-Myers Squibb Co. and Janssen Biotech Inc. GlaxoSmithKline is an Executive level donor.
The Corporate Roundtable is a valuable partnership in the push to advance treatment and find cures. By supporting the Foundation, CRT members play a significant role in improving the health of people with rheumatic diseases.